In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
Related to this article
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Single Infusion of Rese-Cel Yields Meaningful Responses Off Immunomodulators in Phase 1/2 RESET-MG Trial
2
Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP
3
NeuroVoices: James Winkley, MD, on Analyzing Phase 3 PREVAIL Trial of Gefurulimab
4
New Phase 3 Trials to Test Empasiprubart Against Placebo, IVIG in CIDP
5